{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Recorded and reported for each patient, and frequency tables will be reviewed to determine adverse event patterns. These results are reported in the Adverse Events section of this CT.gov report.","groups":[{"description":"Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Lenalidomide: Given PO","id":"OG000","title":"Arm A (Lenalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Pomalidomide: Given PO","id":"OG001","title":"Arm B (Pomalidomide, Dexamethasone)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated patients are evaluable for Adverse Events","reportingStatus":"POSTED","timeFrame":"Up to 30 days after last day of study drug treatment","title":"Number of Participants With Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}